Aspyre Clinical Test product information

Aspyre Clinical Test for Lung provides real solutions for the laboratory

2-Day Turnaround Time

98% of results provided within 2 days vs. 10-14 days with NGS, enabling earlier treatment decisions.

Proven Performance with Challenging Samples

25-40% of lung cancer tissue samples fail NGS. Aspyre provides actionable clinical information from samples deemed to be insufficient quantity (QNS) or failed NGS QC. Challenging samples include pleural effusions, fine needle aspirates and others.¹

High Sensitivity & Specificity 

Aspyre is more sensitive than both NGS and single-gene PCR tests, providing a greater likelihood of detecting an actionable variant.

Tissue or Blood

Can be used on either blood or tissue samples with tumor content as low as 10%. Reflex option to blood if needed.

Directly Analyzes Both DNA and RNA in One Test

The Aspyre Clinical Test for Lung detects somatic mutations from DNA, and gene fusions directly from RNA maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.

Low QC Failure Rates vs. NGS

The Aspyre Clinical Test for Lung has demonstrated successful results in 98% of samples that failed NGS due to QC failure.²

References

1. Hagemann, I. S., Devarakonda, S.,Lockwood, C. et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer, 121(4), 631-639.
2. AACR Poster 2024, https://www.abstractsonline.com/pp8/#!/20272/presentation/10387